Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Optimer Pharmaceuticals Inc. Stories

2013-08-29 08:25:33

Editor Note: For more information about this release, please scroll to bottom. LONDON, August 29, 2013 /PRNewswire/ -- The U.S. equity market ended higher on Wednesday, August 28, 2013. The S&P 500 advanced 0.27%, to close the day at 1,634.96. Shares of companies in the biotechnology industry also ended on a higher note, tracking gains in the broader market. The major movers included Inovio Pharmaceuticals Inc. (NYSE MKT: INO), Onyx Pharmaceuticals Inc. (NASDAQ: ONXX),...

2013-08-01 12:26:43

NEW YORK, Aug. 1, 2013 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Optimer Pharmaceuticals, Inc. ("Optimer" or the "Company") (NasdaqGS: OPTR) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Cubist Pharmaceuticals, Inc. (Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO ) Click here to learn more about the investigation...

2013-08-01 08:34:41

$20.1 million in total net revenues for Q2 2013 JERSEY CITY, N.J., Aug. 1, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the second quarter ended June 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Financial Highlights Second quarter 2013 DIFICID net product sales in the U.S. and Canada of $19.0 million, compared to $15.2 million in the corresponding quarter in 2012, and up 13% from...

2013-05-13 16:27:30

JERSEY CITY, N.J., May 13, 2013 /PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of Mr. Eric Sirota as Chief Operating Officer. Mr. Sirota will be responsible for directing Optimer's corporate strategy with regard to DIFICID®. "Eric has tremendous experience and has demonstrated leadership in building pharmaceutical brands in the United States and abroad and has dedicated his career to making important new...

2013-05-02 08:37:49

JERSEY CITY, N.J., May 2, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) (the "Company" or "Optimer") today announced it will report first quarter 2013 financial results after the NASDAQ Global Market closes on Thursday, May 9. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results and highlights for the first quarter and provide a corporate update. (Logo:...

2013-04-26 08:24:27

Specialised Therapeutics Australia to Launch DIFICID May 14, 2013 JERSEY CITY, N.J., April 26, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Therapeutic Goods Administration, the Australian regulatory body for therapeutic goods such as medicines, has approved DIFICID® (fidaxomicin) tablets for the treatment of confirmed Clostridium difficile infection (CDI) in adults. DIFICID will be available to patients in Australia starting May 14,...

2013-03-15 08:26:38

JERSEY CITY, N.J., March 15, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on March 14, 2013 the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 5,010 shares of common stock to 4 new employees. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Each restricted stock unit vests over three years, with one-third...

2013-02-28 16:29:15

Optimer reports $62.4 million in DIFICID® (fidaxomicin) tablets net product sales for 2012 JERSEY CITY, N.J., Feb. 28, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today unaudited financial results for the fourth quarter and fiscal year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) Financial Highlights 2012 DIFICID net product sales in the U.S. and Canada of $62.4 million, compared to $21.5 million...

2013-02-27 08:29:36

JERSEY CITY, N.J., Feb. 27, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that on February 26, 2013 the Inducement Award Sub-Committee of the Compensation, Nominating, and Corporate Governance Committee of its Board of Directors approved the grant of inducement restricted stock units covering an aggregate of 2,560 shares of common stock to 4 new employees. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) Each restricted stock unit vests...

2013-02-27 08:29:08

COMPANY TO EXPLORE STRATEGIC ALTERNATIVES JERSEY CITY, N.J., Feb. 27, 2013 /PRNewswire/ -- The Board of Directors of Optimer Pharmaceuticals (NASDAQ: OPTR) (the "Company" or "Optimer") today announced the appointment of its Chairman, Dr. Henry McKinnell, as Chief Executive Officer. Dr. McKinnell was associated with Pfizer Inc., from 1971 until his retirement in 2007, including serving as Pfizer's Chief Executive Officer and Chairman from 2001 to 2006. The Board of Directors also...